Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNY – Research Report), Ionis Pharmaceuticals (IONS – Research Report) and Glaukos (GKOS – Research Report).
Alnylam Pharma (ALNY)
Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Alnylam Pharma today and set a price target of $217.00. The company’s shares closed last Thursday at $181.14.
According to TipRanks.com, Tenthoff is a 4-star analyst with an average return of
Currently, the analyst consensus on Alnylam Pharma is a Moderate Buy with an average price target of $232.00, a 28.3% upside from current levels. In a report issued on December 14, Needham also maintained a Buy rating on the stock with a $200.00 price target.
See today’s best-performing stocks on TipRanks >>
Ionis Pharmaceuticals (IONS)
In a report released today, Paul Matteis from Stifel Nicolaus maintained a Hold rating on Ionis Pharmaceuticals, with a price target of $50.00. The company’s shares closed last Thursday at $49.11, close to its 52-week high of $51.89.
According to TipRanks.com, Matteis is a 4-star analyst with an average return of
Currently, the analyst consensus on Ionis Pharmaceuticals is a Moderate Buy with an average price target of $52.33, which is a 7.2% upside from current levels. In a report released yesterday, J.P. Morgan also maintained a Hold rating on the stock.
Glaukos (GKOS)
In a report released today, Matthew O’Brien from Piper Sandler maintained a Buy rating on Glaukos, with a price target of $105.00. The company’s shares closed last Thursday at $85.11, close to its 52-week high of $85.75.
According to TipRanks.com, O’Brien is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Glaukos with a $86.67 average price target, which is a 5.9% upside from current levels. In a report released yesterday, J.P. Morgan also upgraded the stock to Buy with a $91.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ALNY:
- Citi says approval ‘likely’ for Ionis’ eplontersen ATTR-PN NDA
- Alnylam price target raised by $7 at Piper Sandler, here’s why
- Alnylam price target raised by $7 at BofA, here’s why
- Alnylam to hold a virtual research and development day
- Qualcomm downgraded, First Solar upgraded: Wall Street’s top analyst calls
